With its Q4 2025 financials on Thursday, Altimmune (ALT) announced plans to begin a late-stage trial this year to test its lead asset, pemvidutide, in metabolic dysfunction-associated steatohepatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results